This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980
Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479
Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64
Grimm PD, Blasko JD, Sylvester JE, Meier RM, Cavanagh W (2001) 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51:31–40
Han M, Partin AW, Zahurak M et al (2001) Long-termbiochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565
Huggins C, Hodges CV (1941) Studies onprostate cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic cancer of the prostate. Cancer Res 1:293–297
McConnell JD, Bruskewitz R et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563
McConnell JD, Roehrborn CG et al (2003) The long-termeffect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
McNeal JE (1981) The zonal anatomy of the prostate. Prostate 2:35–49
McNeal JE (1988) Normal histology of the prostate. Am J Surg Pathol 12:619–633
Meluch AA, Greco FA, Burris HA et al (2004) Weekly paclitaxel/estramustine phosphate plus carboplatin administered either weekly or every 4 weeks in the treatment of hormone refractory prostate cancer (HRPC): a randomised phase II trial of the Minnie Pearl Cancer Research Network. J Clin Onc 21(14S)(421s): Abstract No. 4659
Mills N, Donovan JL, Smith M et al (2003) Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials 24:272–282
Perez CA, Michalski JM, Mansur D, Lockett MA (2002) Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update. Clin Prostate Cancer 1:97–104
Reiter RE, deKernion JB (2002) Epidemiology, etiology and prevention of prostate cancer. In: Campbell’s urology, 8th edn. WB Saunders, Philadelphia
Roehrborn CG, Boyle P, Nickle JC et al (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441
See WA, Wirth MP et al (2002) Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 168:429–435
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
McNeill, S.A., Leung, S.K.W. (2006). Benign Prostatic Hyperplasia and Prostatic Cancer. In: Schill, WB., Comhaire, F., Hargreave, T.B. (eds) Andrology for the Clinician. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-33713-X_48
Download citation
DOI: https://doi.org/10.1007/3-540-33713-X_48
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23171-4
Online ISBN: 978-3-540-33713-3
eBook Packages: MedicineMedicine (R0)